Navigation Links
Ethicon Completes Acquisition of Acclarent
Date:1/20/2010

SOMERVILLE, N.J., Jan. 20 /PRNewswire/ -- Ethicon, Inc., announced today that it has completed the acquisition of Acclarent, Inc., following clearance under the Hart-Scott-Rodino Antitrust Improvement Act.  Acclarent is a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT). Ethicon announced its agreement to acquire Acclarent on December 16, 2009.

"By bringing together the strengths and experiences of the two companies, we create a unique way to innovate in the surgical ENT space," said Gary Pruden, Johnson & Johnson Company Group Chairman with responsibility for Ethicon.  "The surgical ENT market is underpenetrated and there is opportunity to help more patients restore their quality of life with less-invasive surgical solutions.  We look forward to working with Acclarent and its customers to do this."

About Ethicon

Ethicon, Inc., a Johnson & Johnson company, is a trusted, world-wide leader in surgical care.  For over a century, Ethicon has continuously introduced innovations in wound closure, general surgery, wound management, women's health and urology and aesthetic medicine that fulfill the Company's vision: Restoration of body and of life. For more information, visit www.ethicon.com.

SOURCE Ethicon, Inc.

RELATED LINKS
http://www.ethicon.com

'/>"/>

SOURCE Ethicon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Ethicon Announces Definitive Agreement to Acquire Acclarent
2. Ethicon Endo-Surgery Introduces Innovation-Enabling Solutions Across the Spectrum of Surgery at ACS
3. Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress
4. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
5. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
6. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
7. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
8. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
9. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
10. Dune Medical Completes Enrollment in MarginProbe(TM) Pivotal Trial for Real-Time Detection of Cancer During Breast Conservation Surgery
11. Advanced Cardiac Therapeutics Completes $5 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported ... announced the selection of its,disinfectant, EnviroTru(TM) for ... (Metro). EnviroTru(TM) is a multi-purpose disinfectant ... also meets EPA requirements for,Toxicity Category IV ...
... of statins treated for 3 months with 200 mg/week mipomersen experienced ... continues to support mipomersen,s ... safety profile,- Isis hosting Analyst & Investor Day today - webcast live at 9:00 ... at http://www.isispharm.com , ...
Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 2Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 4Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 5Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 6Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 7
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Restore ... Sen and Dr. Samantha Pearson to help people discover ... avoid corrective vision surgery by instead improving their eyesight ... an investigative review. , “There’s a reason why ... in revenue each year—it’s because people just assume that ...
(Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a historic ... $141 million campus renewal. Renderings of the ... the public. , The new patient tower is part ... campus that meets the needs of patients, families and care ... embody Dayton Children’s unique patient care mission and offer places ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... be, presented at 59th Annual Meeting of the American Association for the ... ... Oct. 31 ,Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ... 59th Annual Meeting of the American Association for the Study,of Live Diseases ...
... CHAPEL HILL, N.C., Oct. 31 Survival nurtures ... rely on their,customers, and employees, innovations in marketing, ... market share., Network with and learn from ... Annual Customer Experience Conference:,Integrated Customer Strategies that Enable ...
... a coma, 6 year chronic sciatica back pain, 15- and ... all these conditions were overcome using advanced magnetic therapy techniques ... ... Pennsylvania (PRWEB) October 31, 2008 -- Regenerating nerves, waking people ...
... published finds that, while about 40 percent of women ... that those issues are a source of significant personal ... Hospital (MGH) physician appears in the November issue of ... are common in women, but problems associated with personal ...
... Normal-weight women who carry out lots of vigorous exercise ... than those who don,t exercise vigorously. A study of ... BioMed Central,s open access journal Breast Cancer Research, ... a risk factor for the disease even in ...
... Nanoparticles Present in 4 out of 5,Sunscreens, Even ... N.Y., Oct. 30 Consumers Union,nonprofit publisher of ... 4 out of 5 sunscreens that claimed not ... urged the FDA to,require a full safety assessment, ...
Cached Medicine News:Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 2Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 3Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 4Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 5Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 6Health News:Survive the Economic Downturn Through Innovations in Integrated Customer Strategies 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 3Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 4Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 5Health News:While prevalent, sexual problems in women not always associated with distress 2Health News:Vigorous activity protects against breast cancer 2Health News:Consumers Union Urges FDA to Conduct Full Scale Safety Review of Nanoparticles in Sunscreen 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: